Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TauroSept is an antimicrobial catheter lock solution developed by Geistlich Pharma AG. It contains 2% taurolidine, a synthetic antimicrobial agent derived from the amino acid taurine. Classified as a medical device, TauroSept is used for the prevention of catheter-related bloodstream infections (CRBSIs) and the maintenance of device patency in central vascular access devices (CVADs). It is administered via local/intraluminal instillation into the catheter between treatments. Taurolidine exerts broad-spectrum activity against gram-positive and gram-negative bacteria, as well as yeasts and molds, by reacting with components of the microbial cell wall and toxins, which minimizes the risk of developing bacterial resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TauroSept.